You have 9 free searches left this month | for more free features.

City

Shanghai (1)

Condition

Metastatic Castration-resistant Prostate Cancer (mCRPC) (1)

Overall Status

Completed (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Jiangsu HengRui Medicine Co., Ltd. (1)

Collaborator

Intervention

abiraterone acetate tablets (i) (1)

zytiga® (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Industry (1)

Study Type

Interventional (1)

zytiga®

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial in Shanghai (Abiraterone Acetate Tablets (I), ZYTIGA®)

Completed

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Abiraterone Acetate Tablets (I)
ZYTIGA®

Shanghai, Shanghai, China

Fudan University Shanghai Cancer Center

Feb 16, 2022